Skip to content
Open access · OA via Europe PMC

CRISPR-based functional genomic screening in neurodegeneration: mechanistic insights into AD, PD, and ALS.

Xue F, Bao L, He A, Liang S.

Frontiers in aging neuroscience · 2026

Abstract

Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), are characterized by pronounced clinical and molecular heterogeneity, as well as highly interconnected pathogenic pathways. This biological complexity has long hindered efforts to systematically define disease mechanisms and to develop effective, targeted therapies. In recent years, clustered regularly interspaced short palindromic repeats (CRISPR) based functional genomic screening technologies have emerged as powerful tools for large-scale genetic perturbation in cellular, organoid, and <i>in vivo</i> models, enabling unbiased interrogation of disease relevant genetic networks and the identification of potential therapeutic targets. In this review, we summarize CRISPR knockout, CRISPR interference, CRISPR activation, and <i>in vivo</i> screening studies in AD, PD, and ALS, with emphasis on pathological phenotypes, experimental models, cell types, validation strategies, and evidence strength. In AD, these screens have identified regulators of amyloid-β (Aβ) production, Tau homeostasis and propagation, microglial states, neuronal aging, and stress responses. In PD, they have provided insights into α-synuclein (α-syn) homeostasis, mitochondrial quality control, lysosomal trafficking, and transplanted dopaminergic neuron survival. In ALS, they have identified modifiers of C9orf72-associated toxicity, repeat-associated non-AUG translation, TAR DNA-binding protein 43 (TDP-43) inclusion formation, and ATXN2 homeostasis. Cross-disease comparison indicates recurring involvement of proteostasis(definition), endolysosomal function, mitochondrial regulation, and cellular stress responses, although individual screening hits show limited overlap and remain strongly influenced by experimental context. Overall, CRISPR-based screening provides a useful framework for identifying candidate disease modifiers, but further validation across complementary human-relevant and <i>in vivo</i> models is required before therapeutic translation.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.3389/fnagi.2026.1831375
Canonical
link ↗
Fetched
2026-10-06 MST

Cite this

APA
F, X., L, B., A, H., &amp; S., L. (2026). CRISPR-based functional genomic screening in neurodegeneration: mechanistic insights into AD, PD, and ALS. <em>Frontiers in aging neuroscience</em>. https://doi.org/10.3389/fnagi.2026.1831375
Vancouver
F X, L B, A H, S. L. CRISPR-based functional genomic screening in neurodegeneration: mechanistic insights into AD, PD, and ALS. Frontiers in aging neuroscience. 2026. doi:10.3389/fnagi.2026.1831375.
BibTeX
@article{xue2026CRISPR, title = {CRISPR-based functional genomic screening in neurodegeneration: mechanistic insights into AD, PD, and ALS.}, author = {Xue F and Bao L and He A and Liang S.}, journal = {Frontiers in aging neuroscience}, year = {2026}, doi = {10.3389/fnagi.2026.1831375}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings